Still struggling with treatment-resistant symptoms?

It could be due to an undiagnosed autoimmune condition that impacts the brain.

An autoimmune response could be causing your neuropsychiatric symptoms.

In some individuals, common infections (i.e., strep, influenza, mycoplasma, Epstein Barr virus and Lyme disease) can trigger an abnormal immune response, whereby antibodies mistakenly target healthy cells in a specific region of the brain, known as the basal ganglia.

This autoimmune attack can be directed towards dopamine receptors, Lysoganglioside and Tubulin or it can stimulate an enzyme (CaMKII) that regulates production of certain neurotransmitters.

This, in turn, can lead to the onset of neurologic and psychiatric symptoms, which may include obsessions/compulsions, tics, anxiety, depression, attention deficit/hyperactivity, seizure-like episodes, eating disorders, and behaviors associated with autism spectrum disorder.

Autoimmune neurospysch get an infection

You get
an infection

When an infectious pathogen (bacteria, virus, fungi, parasites) invades the body, the immune system produces antibodies (or proteins) to destroy the harmful organism.

Antibodies mistakenly attack the brain

Antibodies mistakenly attack the brain

In some people, the immune system goes awry and produces antibodies that mistakenly target portions of healthy cells in an area of the brain, known as the basal ganglia.

Antibodies Target the basal Ganglia

Targeting the
basal Ganglia

These “autoimmune antibodies” can bind to or block neuronal targets (Dopamine D1 and D2 receptors, Lysoganglioside GM-1, Tubulin) in the basal ganglia.

Disrupting how cells function

Disrupting how cells function

When autoimmune antibodies are directed against these targets in the brain, it can disrupt the normal function of cells and receptors.

Triggering Brain Inflammation

Triggering Brain Inflammation

This autoimmune response can also lead to brain inflammation in the basal ganglia, a region of the brain responsible for movement, emotions and thoughts.

Neuropsychiatric Symptoms

Resulting in Neuropsychiatric Symptoms

This, in turn, can lead to the onset of various neurologic, psychiatric and/or behavioral symptoms including OCD, mood disorders, eating disorders, tics and seizure-like episodes.

The Cunningham Panel testing for treatment resistant symptoms
Proper treatment autoimmune neuropsychiatric symptoms

Ordering the Panel is Easy!

The Cunningham Panel™ can only be ordered by licensed healthcare providers authorized to order laboratory tests. The Panel can assist your provider in determining whether your neuropsychiatric symptoms may be due to an underlying infection-triggered autoimmune condition.

Download Requisition form for Cunningham Panel

Requisition Form & Provider Information

Download and take this information to your provider to begin the ordering process. (Requisition for U.S. patients only)

Videos: Ordering & Understanding Test Results

Videos: Ordering & Understanding Test Results

Watch our FAQ videos covering the following topics: billing and insurance, shipping instructions and understanding test results.

How To Order and Costs

How To
Order and Costs

The testing process begins with a licensed clinician submitting a requisition.


Ordering The Cunningham Panel™

The Cunningham Panel™ can only be ordered by licensed healthcare providers authorized to order laboratory tests. We accept orders from all 50 states, as well as other countries. (New York providers can order the test but their patients must have the blood collected outside the state of New York.)

Setup an Account

An Account

Sign-up in our Prescriber Portal to place an order.

Informational Handout For Physician

Cunningham Panel™
Overview Guide

Download guide and learn more about testing with our interactive links.

How To Order and Costs

How To
Order and Costs

Testing process begins with submitting a requisition through our online portal.

  1. Shin Y-W, Lee S-T, Park K-I, et al. Treatment strategies for autoimmune encephalitis. Therapeutic Advances in Neurological Disorders. January 2018. doi:10.1177/1756285617722347
  2. Brenton JN, Goodkin HP. Antibody-Mediated Autoimmune Encephalitis in Childhood. Pediatr Neurol. 2016 Jul;60:13-23. doi: 10.1016/j.pediatrneurol.2016.04.004. Epub 2016 Apr 12. PMID: 27343023.

B. Robert Mozayeni, MD

Medical and Clinical Advisor

B. Robert Mozayeni MD

Dr. B. Robert Mozayeni was trained in Internal Medicine and Rheumatology at Yale and at NIH. He has had pre- and post-doctoral Fellowships in Molecular Biophysics and Biochemistry at Yale, and also at NIH where he was a Howard Hughes Research Scholar at LMB/DCBD/NCI and later, Senior Staff Fellow at LMMB/NHLBI/NIH. Editorial board of Infectious Diseases – Surveillance, Prevention and Treatment. Past President of the International Lyme and Associated Diseases Society (ILADS).

He is an expert in Translational Medicine, the science and art of advancing medical science safely and efficiently. He is a Fellow of the non-profit Think Lead Innovate Foundation and is a co-founder of the Foundation for the Study of Inflammatory Diseases. He is a Founder of the Foundation for the Study of Inflammatory Diseases to crowd-source medical solutions for complex conditions using existing knowledge, diagnostic methods, and therapies to meet patient needs immediately. He is the Chief Medical Officer of Galaxy Diagnostics, LLC. He is a Board member of the Human-Kind Alliance. Dr. Mozayeni has held admitting privileges (since 1994) on the clinical staff of Suburban Hospital, a member of Johns Hopkins Medicine and an affiliate of the National Institutes of Health Clinical Center.

Safedin Sajo Beqaj, PhD, HCLD, CC (ABB)

Moleculera Labs, Clinical Laboratory Advisor
Medical Database, Inc., President and CEO

Sajo Baqaj, PhD

Dr. Sajo Beqaj is board certified in molecular pathology and genetics and licensed as a Bioanalyst and High Complexity Laboratory Director. He has been practicing as a laboratory director since 2005.

Dr. Beqaj served as a technical director and was part of the initial management team for several well-known laboratories in the clinical lab industry including PathGroup, Nashville, TN; DCL Medical Laboratories, Indianapolis, IN, and Pathology, Inc, Torrance, CA. He is currently serving as off-side CLIA laboratory director for BioCorp Clinical Laboratory, Whittier, CA and Health360 Labs, Garden Grove, CA.

Dr. Beqaj received his Ph.D. in Pathology from Wayne State University Medical School, Detroit, Michigan. He performed his post-doctoral fellowship at Abbott Laboratories from 2001-2003 and with Children’s Hospital and Northwestern University from 2003-2005.

Dr. Beqaj has taught in several academic institutions and has published numerous medical textbook chapters and journal articles. He has served as a principal investigator in clinical trials for several well-known pharmaceutical and diagnostic companies such as Roche HPV Athena, Merck HPV vaccine, BD vaginitis panel, Roche (Vantana) CINtec® Histology clinical trials, and has presented various scientific clinical abstracts and presentations.

He is a member of several medical and scientific associations including the Association of Molecular Pathology, American Association of Clinical Chemistry and the Pan Am Society for Clinical Virology. He has served on a number of clinical laboratory regulatory and scientific committees, and has assisted several laboratories and physicians as a Clinical Laboratory Consultant.

Rodney Cotton, MBA

Moleculera Labs Board Member

Rodney Cotton, MBA

Rodney Cotton, MBA is an entrepreneurial thought leader in the pharmaceutical/biotech industry who is known for his holistic perspective, bias for action in the face of challenges, and commitment to agile processes.

Rod is an independent director for Orchard Software, a private equity-backed health technology company owned by Francisco Partners; an advisory board member to Flo2 Ventures, a venture capital-backed healthcare and health equity accelerator; and a member of the board of directors and three board committees (Audit, Compliance & Finance; Governance & Equity; and Quality of Care) for Community Health Network.

He built a successful career at Roche spanning more than two decades and culminating in the role of SVP, Head of Strategy & Transformation, and Chief of Staff to the CEO for Roche Diagnostics, the North American headquarters of the world’s largest ($17B) diagnostics company.

While at Roche, Rod led key enterprise initiatives, such as milestone corporate communications, health equity coalitions, the US/Roche Group audit, and global/US acquisition integrations. With 40+ years of experience, he drove the financial turnaround and cultural transformation of four global healthcare companies, led teams of up to 280 total reports, managed P&L of more than $1 billion, and served as a key member of the senior leadership team executing the most significant restructuring of the company in two decades.

In the face of the COVID-19 pandemic, Rod and his team at Roche accelerated six ground breaking products in 11 months, including the first launch of the market’s most accurate and in demand molecular diagnostic test. He also solved extraordinary challenges of product scarcity, supply chain, product allocation, and logistics to achieve accelerated global sourcing and self manufacturing in line with testing guidelines.

A frequent public speaker on health equity and other topics, Rod was named one of the Most Influential Black Executives in Corporate America by Savoy Magazine and one of the Top Blacks in Healthcare by He also received The Sagamore of the Wabash Award, one of the highest Indiana State honors, bestowed by Indiana Governor Eric J. Holcomb.

Rod holds an M.B.A. from California State University, Dominguez Hills, an M.S. in Strategic Management from the University of Southern California, and a B.A. in Biological Sciences & Technology from the University of California at Santa Barbara.